Jan 10 2011
Receptos, Inc., a biopharmaceutical company, today announces grant of license and technology transfer to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) for Receptos's breakthrough GPCR crystal structure determination technology. The Receptos technology was exclusively licensed from The Scripps Research Institute and has been further advanced by Receptos into the disciplines of drug discovery and development. Following training by Receptos on multiple GPCR targets, the technology will be applied at OMJPI for internal drug discovery efforts in their GPCR pipeline. Financial details of the partnership were not disclosed.
“The relationship with OMJPI is part of the Receptos plan to enable strategic partners with Receptos technology and enhance industry efforts to pursue rational drug design for this important class of therapeutic targets.”
"This unique deal leverages Receptos's core technology and enhances the portfolio of GPCR technology around which Receptos is building knowledge and intellectual property," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The relationship with OMJPI is part of the Receptos plan to enable strategic partners with Receptos technology and enhance industry efforts to pursue rational drug design for this important class of therapeutic targets."
Source: Receptos
Can exercise undo sitting's health risks? New study suggests vigorous activity helps